IVIM Health review: November 2026 prices, terms and what to verify
As of November 20, 2026, IVIM Health’s own page lists "starting at" $117 tirzepatide or $65 semaglutide a month plus a $75 monthly program fee ($192 / $140 all-in at the starting price). On this site’s computed price-and-transparency score it has 8 of 40 points, position 18 of 27 compounded programs.
Released · Last reviewed · how we verify
What IVIM Health charges now
IVIM Health’s prices were read on its own page on November 20, 2026. This site compares programs on the all-in month-to-month price at the maintenance dose, which counts any required membership or program fee and leaves out first-month offers. A 28-day billing cycle means 13 charges a year, not 12.
| Medication | Month to month, all-in | Billing basis | Lowest printed rate | Year at month-to-month price | Read |
|---|---|---|---|---|---|
| Compounded tirzepatide | from $192 | per month, starting-dose price | $192 ($117 + $75 program fee) | — | 2026-11-20 |
| Compounded semaglutide | from $140 | per month, starting-dose price | $140 ($65 + $75 program fee) | — | 2026-11-20 |
IVIM Health on the computed score
On this site’s computed price-and-transparency score it has 8 of 40 points, position 18 of 27 compounded programs. The score covers the two parts of our seven-category methodology that can be checked for every program on the same day: pricing transparency (20 points) and total annual cost (20 points). The full ranking is on the rankings page.
| Check | Tirzepatide | Semaglutide |
|---|---|---|
| prints a month-to-month price | yes (+4) | yes (+4) |
| medication and care in one price | no (0) | no (0) |
| same price at every dose | no (0) | no (0) |
| no membership fee | no (0) | no (0) |
| price read on its own page on November 20, 2026 | yes (+4) | yes (+4) |
| Year at the month-to-month price | no maintenance-dose month-to-month price | no maintenance-dose month-to-month price |
| Total annual cost points | 0 of 20 | 0 of 20 |
| Score for this drug | 8 of 40 | 8 of 40 |
FDA warning letters
FDA’s warning-letter index lists warning letter 721816 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to IVIM Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does IVIM Health charge a membership fee?
Yes. IVIM Health charges a recurring fee of about $75 a month on top of medication, as its page showed on November 20, 2026, and this site folds that fee into every all-in figure.
Does IVIM Health take insurance?
Not for compounded medication. IVIM Health is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does IVIM Health serve?
IVIM Health’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- IVIM Health pricing page (read November 20, 2026)
- FDA warning letter 721816 to IVIM Health (dated 2026-02-20, posted 2026-03-03; read November 20, 2026)